Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates.
暂无分享,去创建一个
S. Ekins | G. Bravi | J. Wikel | S. Wrighton | S A Wrighton | S Ekins | J H Wikel | G Bravi
[1] S. Ekins,et al. Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6. , 1999, The Journal of pharmacology and experimental therapeutics.
[2] S. Ekins,et al. Autoactivation and activation of the cytochrome P450s. , 1998, International journal of clinical pharmacology and therapeutics.
[3] S. Ekins,et al. Further characterization of the expression in liver and catalytic activity of CYP2B6. , 1998, The Journal of pharmacology and experimental therapeutics.
[4] L. Benet,et al. Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[5] A. Rettie,et al. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. , 1998, Biochemistry.
[6] D. Greenblatt,et al. Kinetic Characterization and Identification of the Enzymes Responsible for the Hepatic Biotransformation of Adinazolam and N‐Desmethyladinazolam in Man , 1998, The Journal of pharmacy and pharmacology.
[7] J. Liu,et al. Analysis of four residues within substrate recognition site 4 of human cytochrome P450 3A4: role in steroid hydroxylase activity and alpha-naphthoflavone stimulation. , 1998, Archives of biochemistry and biophysics.
[8] J. Robert,et al. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. , 1998, Cancer research.
[9] D. Lewis,et al. Molecular modelling and quantitative structure-activity relationship studies on the interaction of omeprazole with cytochrome P450 isozymes. , 1998, Toxicology.
[10] L. Bertilsson,et al. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. , 2003, British journal of clinical pharmacology.
[11] H. Kubinyi. QSAR and 3D QSAR in drug design Part 2: applications and problems , 1997 .
[12] D. Shen,et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. , 1997, The Journal of pharmacology and experimental therapeutics.
[13] F. Guengerich,et al. Reconstitution premixes for assays using purified recombinant human cytochrome P450, NADPH-cytochrome P450 reductase, and cytochrome b5. , 1997, Archives of biochemistry and biophysics.
[14] M. Clay,et al. In vitro biotransformation and identification of human cytochrome P450 isozyme-dependent metabolism of tazofelone. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[15] Dennis A. Smith,et al. Properties of cytochrome P450 isoenzymes and their substrates Part 2: properties of cytochrome P450 substrates , 1997 .
[16] Barry C. Jones,et al. Properties of cytochrome P450 isoenzymes and their substrates Part 1: active site characteristics , 1997 .
[17] B H Arison,et al. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[18] L. Benet,et al. Cytochrome P4503A4-mediated N-demethylation of the antiprogestins lilopristone and onapristone. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[19] D. Lewis,et al. In vitro metabolism of dexamethasone (DEX) in human liver and kidney: the involvement of CYP3A4 and CYP17 (17,20 LYASE) and molecular modelling studies. , 1997, Biochemical pharmacology.
[20] G. Nelsestuen,et al. Steady state enzyme velocities that are independent of [enzyme]: an important behavior in many membrane and particle-bound states. , 1997, Biochemistry.
[21] J. Halpert,et al. Identification of three key residues in substrate recognition site 5 of human cytochrome P450 3A4 by cassette and site-directed mutagenesis. , 1997, Biochemistry.
[22] M. Murray,et al. Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. , 1997, The Journal of pharmacology and experimental therapeutics.
[23] T. Koudriakova,et al. Metabolism of rifabutin in human enterocyte and liver microsomes: Kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents , 1997, Clinical pharmacology and therapeutics.
[24] Grazyna D. Szklarz,et al. Molecular modeling of cytochrome P450 3A4 , 1997, J. Comput. Aided Mol. Des..
[25] A. D. Rodrigues,et al. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[26] F. Berthou,et al. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. , 1997, Life sciences.
[27] A. Y. Lu,et al. Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation. Competition during catalysis. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[28] James R. Halpert,et al. Alanine-scanning Mutagenesis of a Putative Substrate Recognition Site in Human Cytochrome P450 3A4 , 1997, The Journal of Biological Chemistry.
[29] A. P. Koley,et al. Drug-drug interactions: effect of quinidine on nifedipine binding to human cytochrome P450 3A4. , 1997, Biochemical pharmacology.
[30] P. Souček,et al. Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation. , 1997, Biochemical pharmacology.
[31] Roberto Todeschini,et al. MS-WHIM, new 3D theoretical descriptors derived from molecular surface properties: A comparative 3D QSAR study in a series of steroids , 1997, J. Comput. Aided Mol. Des..
[32] K. Chiba,et al. Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human live microsomes and nine recombinant human cytochromes P450. , 1996, The Journal of pharmacology and experimental therapeutics.
[33] S K Balani,et al. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[34] L. Benet,et al. Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes. , 1996, Biochemical pharmacology.
[35] J. Lasker,et al. Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[36] P. Thomas,et al. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[37] D. Lewis,et al. Molecular modelling of CYP1A subfamily members based on an alignment with CYP102: rationalization of CYP1A substrate specificity in terms of active site amino acid residues. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.
[38] L. Wienkers,et al. Biotransformation of tirilazad in human: 1. Cytochrome P450 3A-mediated hydroxylation of tirilazad mesylate in human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.
[39] B. K. Park,et al. Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. , 1996, The Journal of pharmacology and experimental therapeutics.
[40] A. D. Rodrigues,et al. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.
[41] G. de Sousa,et al. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. , 1996, Cancer research.
[42] P. Maurel,et al. Metabolism of the new immunosuppressor cyclosporin G by human liver cytochromes P450. , 1996, Biochemical pharmacology.
[43] S. Binkley,et al. Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor. , 1996, Pharmacogenetics.
[44] D. Greenblatt,et al. Characterization of six in vitro reactions mediated by human cytochrome P450: application to the testing of cytochrome P450-directed antibodies. , 1996, Pharmacology.
[45] D A Smith,et al. Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase). , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[46] M H Tarbit,et al. Molecular modelling of CYP3A4 from an alignment with CYP102: identification of key interactions between putative active site residues and CYP3A-specific chemicals. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.
[47] A. D. Rodrigues,et al. Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[48] D. Mansuy,et al. The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling. , 1995, Biochemistry.
[49] A. D. Rodrigues,et al. In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[50] D. Lewis. Three-dimensional models of human and other mammalian microsomal P450s constructed from an alignment with P450102 (P450bm3). , 1995, Xenobiotica; the fate of foreign compounds in biological systems.
[51] A. P. Koley,et al. CO Binding Kinetics of Human Cytochrome P450 3A4 , 1995, The Journal of Biological Chemistry.
[52] H. Yamazaki,et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.
[53] D. Kroetz,et al. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. , 1994, Biochemical pharmacology.
[54] K. Korzekwa,et al. Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. , 1994, Biochemistry.
[55] S. Wrighton,et al. In vitro metabolism of zatosetron. Interspecies comparison and role of CYP 3A. , 1994, Drug metabolism and disposition: the biological fate of chemicals.
[56] T. Walle,et al. Cytochrome P450 3A-mediated human liver microsomal taxol 6 alpha-hydroxylation. , 1994, The Journal of pharmacology and experimental therapeutics.
[57] H. Yamazaki,et al. Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. , 1994, Biochemical pharmacology.
[58] R. Branch,et al. Monoacetyldapsone inhibition of dapsone N-hydroxylation by human and rat liver microsomes. , 1994, Drug metabolism and disposition: the biological fate of chemicals.
[59] S. M. Abel,et al. Cortisol metabolism in vitro—III. Inhibition of microsomal 6β—hydroxylase and cytosolic 4-ene-reductase , 1993, The Journal of Steroid Biochemistry and Molecular Biology.
[60] J. Miners,et al. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. , 1993, British journal of clinical pharmacology.
[61] X. J. Zhou,et al. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. , 1993, Cancer research.
[62] F. Guengerich,et al. Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions. , 1993, Drug Metabolism And Disposition.
[63] X. J. Zhou,et al. Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions. , 1993, Biochemical pharmacology.
[64] D A Smith,et al. Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. , 1992, Biochemical pharmacology.
[65] F. Gonzalez,et al. Cytochrome P-450 3A4 (nifedipine oxidase) is responsible for the C-oxidative metabolism of 1-nitropyrene in human liver microsomal samples. , 1992, Cancer research.
[66] U. Christians,et al. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. , 1992, Drug metabolism and disposition: the biological fate of chemicals.
[67] S A van Acker,et al. A predictive model for substrates of cytochrome P450-debrisoquine (2D6). , 1992, Chemical research in toxicology.
[68] M. Eichelbaum,et al. Predictability of the in vivo metabolism of verapamil from in vitro data: contribution of individual metabolic pathways and stereoselective aspects. , 1992, The Journal of pharmacology and experimental therapeutics.
[69] S. Wrighton,et al. The human hepatic cytochromes P450 involved in drug metabolism. , 1992, Critical reviews in toxicology.
[70] P. Beaune,et al. Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. , 1991, Biochemical pharmacology.
[71] C. Miranda,et al. Role of cytochrome P450IIIA4 in the metabolism of the pyrrolizidine alkaloid senecionine in human liver. , 1991, Carcinogenesis.
[72] P. Maurel,et al. Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. , 1990, Drug metabolism and disposition: the biological fate of chemicals.
[73] György G. Ferenczy,et al. The active site of cytochrome P-450 nifedipine oxidase: a model-building study. , 1989, Journal of molecular graphics.
[74] T. Kronbach,et al. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. , 1989, Molecular pharmacology.
[75] I Skånberg,et al. In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. , 2009, Acta pharmacologica et toxicologica.
[76] F. Guengerich,et al. Oxidation of quinidine by human liver cytochrome P-450. , 1986, Molecular pharmacology.
[77] D. Waxman,et al. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. , 1986, The Journal of biological chemistry.